COO Cooper Companies Inc.

CooperCompanies Appoints Cynthia Lucchese to Board of Directors

CooperCompanies Appoints Cynthia Lucchese to Board of Directors

SAN RAMON, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) announced today that its Board of Directors has appointed Cynthia Lucchese as an independent director, effective October 1, 2022. Lucchese has also been appointed to serve on the Audit Committee and Corporate Governance and Nominating Committee when she joins the Board.

“We are pleased to welcome Cindy to Cooper’s Board of Directors,” said Al White, President and CEO of CooperCompanies. “She is a highly successful executive with a strong strategic, financial, and operational background. We are confident that her business acumen and board experiences will benefit Cooper and our shareholders."

Lucchese currently serves as Chief Strategy Officer of Penske Entertainment, a subsidiary of Penske Corporation. She previously served as Chief Administrative and Financial Officer of Hulman & Company (acquired by Penske Corporation) from 2014 to 2020. Prior to this, she was Senior Vice President and Chief Financial Officer of Hillenbrand from 2008 to 2014 and of Thoratec Corporation from 2005 to 2007. Lucchese also spent more than a decade at Guidant Corporation (acquired by Boston Scientific) serving in a variety of leadership roles including Vice President and Corporate Treasurer, and she worked for Eli Lilly & Company earlier in her career.

Lucchese serves on the Boards of Directors of Inari Medical Inc. and Beaver-Visitec International Holdings. She also serves on the Board of Trustees of Indiana University. Lucchese received her Bachelor of Science in accounting and Master of Business Administration from Indiana University.

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of roughly 14,000 with products sold in over 100 countries. For more information, please visit .

Contact:

Kim Duncan

Vice President, Investor Relations and Risk Management

925-460-3663



EN
03/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

Cooper Companies Inc: 3 directors

A director at Cooper Companies Inc bought 2,000 shares at 82.500USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

CooperCompanies Announces New Chair of the Board and Strategic Review

CooperCompanies Announces New Chair of the Board and Strategic Review SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that its Board of Directors has appointed Colleen Jay to succeed current Chair Robert Weiss, effective January 2, 2026. Mr. Weiss will remain on the Board and stand for reelection for the upcoming year, marking his final term. The Company also announced a formal strategic review aimed at identifying opportunities to enhance long-term shareholder value. “Bob’s vision, industry knowledge, ...

 PRESS RELEASE

CooperCompanies Announces Fourth Quarter and Full Year 2025 Results

CooperCompanies Announces Fourth Quarter and Full Year 2025 Results SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025. Fourth quarter 2025 revenue of $1,065.2 million, up 5%, or up 3% organically. Fiscal year 2025 revenue of $4.1 billion, up 5%, or up 4% organically.Fourth quarter 2025 GAAP diluted earnings per share (EPS) of $0.43, down 27%. Fiscal 2025 GAAP diluted EPS of $1.87, down 4%.Fourth quarter 2025 non-GA...

 PRESS RELEASE

CooperCompanies Announces Release Date for Fourth Quarter and Full Yea...

CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025 SAN RAMON, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results on Thursday, December 4, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2700541. A simultaneous audio webcast and subsequent replay c...

 PRESS RELEASE

CooperCompanies Announces Expanded Share Repurchase Program

CooperCompanies Announces Expanded Share Repurchase Program SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase in the Company’s share repurchase program. The share repurchase program now totals $2 billion. “We are pleased to announce that our Board of Directors has authorized an increase to our share repurchase program,” said Al White, President and Chief Executive Officer. “This decision underscores the strength of our balance sheet and cas...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch